ClinicalTrials.gov record
Terminated Phase 1 Interventional

A Study of PY314 in Subjects With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT04691375

Public ClinicalTrials.gov record NCT04691375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 3:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1a/1b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Study identification

NCT ID
NCT04691375
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Ikena Oncology
Industry
Enrollment
86 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 28, 2020
Primary completion
Aug 30, 2023
Completion
Sep 21, 2023
Last update posted
Mar 21, 2024

2020 – 2023

United States locations

U.S. sites
23
U.S. states
17
U.S. cities
21
Facility City State ZIP Site status
Mayo Clinic Scottsdale - PPDS Phoenix Arizona 85054
Honor Health Research Institute Scottsdale Arizona 85258-4566
City of Hope - Comprehensive Cancer Center Duarte California 91010
Stanford Hospital and Clinics Palo Alto California 94304
UC San Diego Moores Cancer Center San Diego California 92093
University of Colorado Hospital Aurora Colorado 80045
Mayo Clinic Jacksonville - PPDS Jacksonville Florida 32224
H Lee Moffitt Cancer Center and Research Institute Tampa Florida 33612
University of Chicago Chicago Illinois 60637
Massachusetts General Hospital Boston Massachusetts 02214
Dana-Farber Cancer Institute Boston Massachusetts 02215
Karmanos Cancer Institute Detroit Michigan 48201
Mayo Clinic - PPDS Rochester Minnesota 55905
Icahn School of Medicine at Mount Sinai New York New York 10029
The Cleveland Clinic Foundation Cleveland Ohio 44195
University of Oklahoma Peggy and Charles Stephenson Cancer Center Oklahoma City Oklahoma 73104
OHSU Knight Cancer Institute Beaverton Clinic Portland Oregon 97239
Thomas Jefferson University Philadelphia Pennsylvania 19107
Sarah Cannon Research Institute Nashville Tennessee 37203
Vanderbilt Ingram Cancer Center Nashville Tennessee 37232
Start South Texas Accelerated Research Therapeutics San Antonio Texas 78229
NEXT Virginia Fairfax Virginia 22031
Wisconsin Institutes for Medical Research Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04691375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 21, 2024 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04691375 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →